Description: HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Home Page: www.hillevax.com
HLVX Technical Analysis
75 State Street
Boston,
MA
02109
United States
Phone:
617 213 5054
Officers
| Name | Title |
|---|---|
| Dr. Robert M. Hershberg M.D., Ph.D. | Pres, CEO & Chairman |
| Mr. David A. Socks | CFO & Chief Bus. Officer |
| Mr. Aditya Kohli Ph.D. | COO & Director |
| Dr. Anju Chatterji Ph.D. | Sr. VP of Technical Operations |
| Mr. Paul S. Bavier J.D. | Gen. Counsel, Sec. & Chief Admin. Officer |
| Ms. Astrid Borkowski M.D., Ph.D. | Chief Medical Officer |
| Ms. Kaia Agarwal | Sr. VP of Regulatory Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7579 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-04-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 15 |